Dallas, Texas 08/06/2013 (Financialstrend) – Succesful testing of the HIF-1 to help mankind Inovio Pharmaceuticals Inc (NYSEMKT:INO) has announced that the use of its proficient proprietary electroporation technology has yielded positive returns. The technology seems to have significantly enhanced the ability of DNA therapy to stimulate an impressive growth of the blood vessels. The results are expected to be beneficial to treat numerous forms of the Peripheral Arterial Disease including the critical limb ischemia (CLI).
The peculiar CLI is potent of causing blockage of arteries hence resulting in negative impacts on health and even death. Hence, the cure of it is imperative to the mankind.
At present, the experiments have been conducted on the animal models.
The Arterial disease affects almost 12 million people in America where 20-30% of the cases end with death. CLI is even more haunting a disease as the five year mortality rate exceeds a whopping 70%. Upto 20% people die within a year of diagnosis.
In this particular experimental study, the gene factor HIF-1 was synthetically optimised to enhance the growth factor and as of now the results on the animal models have been very promising.
Response To Market Activities
The Inovio Pharmaceuticals (NYSEMKT:INO) has announced that the Exchange has eventually contracted the company in contrast to its natural practice. This announcement is based on the queer market activity that arose in the company’s stock.
The pharmaceutical company (NYSEMKT:INO) aims at revolutionising the various vaccines to curb and uproot the modern day diseases like cancers and other infectious diseases. The SynCon vaccines in combination with the proprietary electroporation delivery have been generating the best immune responses till date. Also numerous other vaccines have been initiated or are being worked upon with the aim of providing the best possible health assistance to the mankind.
Also the company has been working upon many health programmes including even those of the military.